ATS 2019 Virtual Final Program

508 Exhaled Breath Analysis for Prediction of Responders to Mepolizumab in Patients with Severe Asthma/ J.J.M.H. van Bragt, R. de Vries, P.J. Sterk, A.H. Maitland-van der Zee, Amsterdam, Netherlands, p.A2673 509 Meta-Analysis of Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab/ J.-P. Llanos Ackert, M.S. Forshag, D. Carstens, B. Mayer, F. Albers, M. Liu, Research Triangle Park, NC, p.A2674 510 Response to Benralizumab After Sub-Optimal Response to Mepolizumab in Oral Corticosteroid Dependent Severe Eosinophilic Asthma/ J. Kavanagh, L. Green, M. Fernandes, C. Roxas, B.D. Kent, D.J. Jackson, G. d’Ancona, London, United Kingdom, p.A2675 511 Two-Year Integrated Efficacy and Safety Analysis of Benralizumab SIROCCO, CALIMA, ZONDA, and BORA Trials in Severe Asthma/ J.M. Fitzgerald, E.R. Bleecker, A. Bourdin, W.W. Busse, G.T. Ferguson, L. Brooks, P. Barker, U. Martin, Vancouver, Canada, p.A2676 512 Tezepelumab Reduces Multiple Key Inflammatory Biomarkers in Patients with Severe, Uncontrolled Asthma in the Phase 2b PATHWAY Study/ T.-H. Pham, P. Ren, J.R. Parnes, J.M. Griffiths, Gaithersburg, MD, p.A2677 513 Characteristics of US, Subspecialist-Treated Adults with Severe Asthma Receiving and Not Receiving Therapy with Biologic Medications in the CHRONICLE Study/ C. Ambrose, W. Carr, B.E. Chipps, D.K. Ledford, N. Lugogo, W.C. Moore, W. Soong, J. Trevor, R.A. Panettieri, L. Belton, F. Trudo, Gaithersburg, MD, p.A2678 514 Real-World Biologic Medication Use in a Diverse Population of US, Specialist-Treated Adults with Severe Asthma -Results of CHRONICLE Study/ W.C. Moore, W. Carr, B.E. Chipps, D. Ledford, N. Lugogo, R.A. Panettieri, W. Song, J. Trevor, L. Belton, F. Trudo, C.S. Ambrose, Winston-Salem, NC, p.A2679 515 Insensitivity to Corticosteroids Predicts Longitudinal Loss of Lung Function in the NHLBI Severe Asthma Research Program (SARP III)/ L.C. Denlinger, B.R. Phillips, R.L. Sorkness, E.R. Bleecker, M. Castro, A.M. Fitzpatrick, B.M. Gaston, A.T. Hastie, M.C. Peters, S.P. Peters, S.E. Wenzel, N.N. Jarjour, D.T. Mauger, E. Israel, Madison, WI, p.A2680 516 Characteristics by Provider Subspecialty of Patients Enrolled in the CHRONICLE Study: A Real-World, Prospective, Observational Study of US, Subspecialist-Treated Adults with Severe Asthma/ R.A. Panettieri, W. Carr, B.E. Chipps, D.K. Ledford, N. Lugogo, W.C. Moore, W. Soong, J. Trevor, L. Belton, F. Trudo, C.S. Ambrose, New Brunswick, NJ, p.A2681 517 Adherence Assessment in Clinical Trials of Severe Asthma Therapy Is Inadequate and Leads to Loss of Power/ G. Greene, M.C. Mokoka, E. MacHale, R.W. Costello, Dublin, Ireland, p.A2682 518 Long-Term Efficacy and Safety of Bronchial Thermoplasty (BT): 4 Year Follow-Up Results from a Large Scale Prospective Study/ G.L. Chupp, J.N. Kline, S.B. Khatri, C.E. McEvoy, G.A. Silvestri, A. Shifren, M. Castro, S. Bansal, M.R. McClelland, M.T. Dransfield, R. Olivenstein, R. Kahlstrom, S. Ryan, E. Lawson, M.J. Simoff, M.M. Wahidi, C.R. Lamb, J.S. Ferguson, A. Haas, D.K. Hogarth, R.S. Tejedor, J.W. Toth, A. Majid, J.M. Fitzgerald, K.B. Enfield, G.M. Grubb, M. Laviolette, New Haven, CT, p.A2683 519 Insulin Resistance Is Associated with Longitudinal Decline in Lung Function in the Severe Asthma Research Program/ M.C. Peters, M. Schiebler, E.R. Bleecker, M. Castro, S.C. Erzurum, A.T. Hastie, B.D. Levy, J.C. Cardet, E. Israel, B. Phillips, D. Mauger, M.W. Johansson, S.E. Wenzel, N.N. Jarjour, J.V. Fahy, San Francisco, CA, p.A2684 520 Combined Immune Response Based on Bal Cytokine Profiling in Children with Severe Asthma/ E. Chorvinsky, K. Salka, Z. Barnawi, A. Alyami, S. Naime, J.H. Jackson, D.K. Pillai, Washington, DC, p.A2685 521 Sputum Eosinophil Stability Compared to Variability Over 3 Years in the NHLBI Severe Asthma Research Program (SARP) Cohort/ A.T. Hastie, D. Mauger, L.C. Denlinger, E. Israel, A.M. Coverstone, J.V. Fahy, M.L. Fajt, B. Phillips, E.R. Bleecker, Winston-Salem, NC, p.A2686 522 Investigation of IL-6 and IL-6R levels as Biomarkers for Asthma Severity and Asthma Exacerbations/ X. Li, A.T. Hastie, M.C. Peters, G.A. Hawkins, H. Li, W.C. Moore, M. Castro, B. Gaston, E. Israel, N.N. Jarjour, B.D. Levy, S.E. Wenzel, D.A. Meyers, J.V. Fahy, E.R. Bleecker, Tucson, AZ, p.A2687 523 A Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial with Withdrawal Design of AZD1419, a Toll-9 Agonist in Adults with Eosinophilic, Moderate to Severe Asthma/ I. Psallidas, V. Backer, P. Kuna, L. Molnar, M. Aurell, K. Korsback, R. Palmer, Z. Taib, M. Hashemi, S. Necander, P. Gustafsson, S. Asimus, S. Delaney, K. Pardali, S. Jackson, R.L. Coffman, D. Keeling, T. Sethi, Gothenburg, Sweden, p.A7361 524 Efficacy and Safety of High ICS Dose Fixed-Combination ICS/LABA/LAMA pMDI Compared with ICS/LABA and ICS/LABA + LAMA in Patients with Uncontrolled Asthma: The TRIGGER Study/ G.W.W. Canonica, J.C. Virchow, M. Kots, F. Zuccaro, E. Carzana, A. Vele, G. Georges, S. Petruzzelli, Milano, Italy, p.A7362 525 Reducing the Rate of Severe Asthma Exacerbations Using Single-Inhaler Extrafine BDP/FF/GB Combination Compared to BDP/FF in Patients with Uncontrolled Asthma: Pooled Results from the TRIMARAN and TRIGGER Studies/ J.C. Virchow, W.G. Canonica, P. Paggiaro, M. Kots, S. Corre, F. Zucarro, E. Carzana, A. Vele, G. Georges, S. Petruzzelli, Rostock, Germany, p.A7363 BEHAVIORAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION B22 CRITICAL ILLNESS MANAGEMENT AND OUTCOMES 9:15 a.m. - 11:15 a.m. KBHCCD Arena (Level 2) Abstract Summaries 9:15-9:45 Viewing/Discussion 9:45-11:15 Chairing: A.J. Admon, MD, MPH, Ann Arbor, MI B.E. Jones, MD, MSc, Salt Lake City, UT D.J. Murphy, PhD, MD, Atlanta, GA ATS 2019 • Dallas, TX 134 MONDAY • MAY 20